Neoprobe 3rd Quarter 2011 Earnings and Business Update Conference Call Invitation

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced it would report its financial results for the third quarter of 2011 on Wednesday, October 26, 2011 after market close. The announcement will be followed by a conference call with the investment community the following day, Thursday, October 27 at 8:30 am ET.

Neoprobe’s President and CEO, Dr. Mark Pykett, Senior Vice President, Pharmaceutical Research and Clinical Development, Dr. Fred Cope, and Senior Vice President and CFO, Brent Larson, will provide a development and business update and will discuss the Company’s financial results for the third quarter of 2011 during the conference call. The conference call can be accessed as follows:

Conference Call Information

TO PARTICIPATE LIVE:

TO LISTEN TO A REPLAY:

        
        
        
      
      
        
          Date:

          

Time:

 

Toll-free (U.S.) Dial in # :

International Dial in # :

        
        
           
        
        
          Oct 27, 2011

          

8:30 AM ET

 

[phone]

[phone]

        
        
        
        
          Available until:

          

Toll-free (U.S.) Dial in # :

International Dial in # :

 

Replay passcode:

Account #:

Conference ID #:

        
        
           
        
        
          Nov 10, 2011

          

[phone]

[phone]

 

 

286

381791

About Neoprobe

Neoprobe Corporation (NYSE Amex: NEOP) is a biomedical company focused on enhancing oncology patient care and improving patient benefit through radiopharmaceutical product development. Neoprobe is actively developing two radiopharmaceutical agent platforms – Lymphoseek® and RIGScanTM CR – to help surgeons better identify and treat certain types of cancer. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also exploring development of a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline program through continued investment and selective acquisitions. For more information, please visit www.neoprobe.com.